Biolizard: Alexander Scheer joins leadership team to advance AI-driven solutions
BioLizard appointed Dr. Alexander Scheer as Chief Scientific Officer to scale its multi-omics and AI biomarker platform. He brings 25+ years of translational R&D experience across oncology, biologics, and clinical development at firms including Merck, Erytech, and CasInvent.
Why it mattersBioLizard's CSO hire strengthens multi-omics and AI biomarker capabilities; consider partnership or vendor opportunities for precision-medicine.
Entities Mentioned
BioLizardCasInvent PharmaAelin TherapeuticsErytech PharmaPierre FabreMerckSeronoUniversity of GöttingenGerman Cancer Research Centre (DKFZ
People Mentioned
Alexander ScheerLiesbeth Ceelen